Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05594953 · ClinicalTrials.gov registry record
Outcomes Using MARS for Patients With ALF
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 27
- Enrollment target
NCT05594953: Completed study, sponsored by Methodist Health System.
NCT05594953 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05594953 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures.
Primary Outcome
transplant will be measured by date of death, and discharge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-04-23 |
| Est. Completion | 2026-05-12 |
What the finished NCT05594953 record still lists
NCT05594953 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05594953 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05594953 about?
NCT05594953 is a clinical study titled "Outcomes Using MARS for Patients With ALF". Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures.
What is the current status of trial NCT05594953?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2021-04-23. Estimated completion is 2026-05-12.
Who is sponsoring clinical trial NCT05594953?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI